Icade SA
PAR:ICAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Icade SA
Common Stock
Icade SA
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Icade SA
PAR:ICAD
|
Common Stock
€116.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Gecina SA
PAR:GFC
|
Common Stock
€575.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Patrimoine et Commerce SCA
PAR:PAT
|
Common Stock
€158.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
|
Immobiliere Dassault SA
PAR:IMDA
|
Common Stock
€46m
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Atland SA
PAR:ATLD
|
Common Stock
€49.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Bleecker SA
PAR:BLEE
|
Common Stock
€20.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Icade SA
Glance View
In the bustling world of real estate, Icade SA carves out a unique niche as a pivotal player in the French market. Born out of the Caisse des Dépôts conglomerate, Icade is rooted in a tradition of resilience and innovation. The company intricately weaves its operations across three primary areas: property investment, healthcare real estate, and property development. Its property investment arm predominantly deals with office spaces, strategically positioned in major urban hubs like Paris and its environs. This focus allows Icade to benefit from steady rental income, often buoyed by long-term leases to prestigious clients. Meanwhile, its healthcare property segment addresses the ever-growing demand for medical facilities, acquiring and leasing spaces to operators, thereby tapping into a sector that's not only resilient but poised for growth amidst demographic changes. Complementing these robust investments, Icade's property development division injects dynamism into its portfolio. Here, Icade engages in the creation of new residential and commercial properties, harnessing its expertise to meet the evolving architectural and technological needs of modern living and working spaces. This diversification not only provides Icade with direct revenue streams from sales and leasing but also enhances its asset management prowess, increasing its appeal to investors and stakeholders. In essence, Icade’s business model thrives on a balanced interplay between secure, long-term rental income and the lucrative, albeit more volatile, profits from property development. The company’s strategic diversification within the real estate market underscores a commitment to both stability and growth, ensuring that it remains a formidable force in its domain.
See Also
What is Icade SA's Common Stock?
Common Stock
116.2m
EUR
Based on the financial report for Dec 31, 2025, Icade SA's Common Stock amounts to 116.2m EUR.
What is Icade SA's Common Stock growth rate?
Common Stock CAGR 10Y
0%
Over the last year, the Common Stock growth was 0%.